Progress of histone deacetylase inhibitors in treatment of non-Hodgkin lymphoma / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
;
(12): 573-576, 2020.
Artículo
en Chino
| WPRIM
| ID: wpr-862880
ABSTRACT
At present, there are few treatment protocols with limited efficacy for relapsed and refractory non-Hodgkin lymphoma (NHL). Histone deacetylase inhibitors (HDACi) exert anti-tumor effects by inhibiting the activation of histone deacetylase (HDAC) and regulating gene expression. HDACi alone or combined with other anti-tumor drugs have shown good efficacy in the treatment of relapsed and refractory NHL. This article reviews the progress of HDACi in the treatment of NHL.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Tipo de estudio:
Guía de Práctica Clínica
Idioma:
Chino
Revista:
Journal of Leukemia & Lymphoma
Año:
2020
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS